LON:PRMProteome Sciences Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 2.92 -0.08 (-2.67 %) (As of 04/7/2020 01:15 AM ET) Add Compare Share Today's Range 2.65Now: GBX 2.92▼ 3.1050-Day Range 2.64MA: GBX 3.22▼ 3.6052-Week Range 2.25Now: GBX 2.92▼ 4.30Volume485,560 shsAverage Volume88,695 shsMarket Capitalization£8.62 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartInsider TradesHeadlines Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, isobaric reagents, and biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes. It primarily serves pharmaceutical companies and other sectors, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Proteome Sciences. Previous Next 2.0 Community Rank Outperform VotesProteome Sciences has received 162 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProteome Sciences has received 245 “underperform” votes. (Add your “underperform” vote.)Community SentimentProteome Sciences has received 60.20% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Proteome Sciences and other stocks. Vote “Outperform” if you believe PRM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProteome Sciences does not currently pay a dividend.Dividend GrowthProteome Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Proteome Sciences insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Proteome Sciences is -29.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Proteome Sciences is -29.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.40 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Medical Laboratories & Research Sub-IndustryN/A SectorMedical Current SymbolLON:PRM Previous Symbol CUSIPN/A CIKN/A Webhttp://www.proteomics.com/ Phone+44-20-70432116Debt Debt-to-Equity RatioN/A Current Ratio0.31 Quick Ratio0.22Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£3.47 million Price / Sales2.49 Cash FlowGBX 0.28 per share Price / Cash Flow10.50 Book ValueGBX (1.40) per share Price / Book-2.09Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees29 Outstanding Shares295,182,016Market Cap£8.62 million Next Earnings DateN/A OptionableNot Optionable Receive PRM News and Ratings via Email Sign-up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter. LSE:PRM Rates by TradingView Proteome Sciences (LON:PRM) Frequently Asked Questions How has Proteome Sciences' stock been impacted by COVID-19 (Coronavirus)? Proteome Sciences' stock was trading at GBX 3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRM stock has decreased by 10.2% and is now trading at GBX 2.92. View which stocks have been mosted impacted by Coronavirus. Has Proteome Sciences been receiving favorable news coverage? Media stories about PRM stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Proteome Sciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutProteome Sciences. Who are some of Proteome Sciences' key competitors? Some companies that are related to Proteome Sciences include VolitionRX (VNRX), Spectral Medical (EDT), ANGLE (AGL), DiaSorin (DIA), Polarityte (COOL) and Premaitha Health (NIPT). What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), Boohoo Group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), Cyanconnode (CYAN) and Eckoh (ECK). Who are Proteome Sciences' key executives? Proteome Sciences' management team includes the following people: Dr. Jeremy Rupert Michael Haigh, CEO & Exec. Director (Age 58)Dr. Ian H. Pike, Chief Scientific Officer & Exec. DirectorMr. Richard Paul Dennis, Chief Commercial Officer & Exec. Director (Age 60)Mr. Stefan Fuhrmann, Interim Fin. DirectorDr. Josef Schwarz, Chief Compliance Officer What is Proteome Sciences' stock symbol? Proteome Sciences trades on the London Stock Exchange (LON) under the ticker symbol "PRM." How do I buy shares of Proteome Sciences? Shares of PRM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Proteome Sciences' stock price today? One share of PRM stock can currently be purchased for approximately GBX 2.92. How big of a company is Proteome Sciences? Proteome Sciences has a market capitalization of £8.62 million and generates £3.47 million in revenue each year. Proteome Sciences employs 29 workers across the globe. View additional information about Proteome Sciences. What is Proteome Sciences' official website? The official website for Proteome Sciences is http://www.proteomics.com/. How can I contact Proteome Sciences? Proteome Sciences' mailing address is Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom. The company can be reached via phone at +44-20-70432116. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is quantitative easing?
